Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phthalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.44 |
| ▸ | GGT1 | P19440 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalic Acid SCHEMBL321766 | 0.96 | ALDH1A1 (0.54) | ALDH1A1ALOX15KDM4ETSHRHPGD | |
| Salicylic Acid SCHEMBL2882428 | 0.86 | ALDH1A1 (0.60) | ALDH1A1ALOX15KDM4ETSHRHPGD | |
| SCHEMBL6903418 | 0.85 | ALDH1A1 (0.57) | ALDH1A1ALOX15KDM4ETSHRHPGD | |
| Salicylic Acid SCHEMBL4624747 | 0.85 | KDM4E (0.58) | ALDH1A1ALOX15KDM4ETSHRHPGD | |
| SCHEMBL7568179 | 0.82 | MEN1 (0.43) | ALDH1A1ALOX15KDM4ETSHRHPGD | |
| Formaldehyde SCHEMBL1582461 | 0.81 | KDM4E (0.47) | ALDH1A1ALOX15KDM4ETSHRHPGD | |
| Phthalic Acid SCHEMBL15861421 | 0.81 | ALDH1A1 (0.58) | ALDH1A1ALOX15KDM4ETSHRHPGD | |
| Acetic Acid SCHEMBL23907968 | 0.80 | LMNA (0.67) | ALDH1A1ALOX15TSHRHSD17B10TDP1 | |
| Acetic Acid SCHEMBL222953 | 0.80 | LMNA (0.67) | ALDH1A1ALOX15TSHRHSD17B10TDP1 | |
| Acetophenone SCHEMBL6684394 | 0.80 | LMNA (0.47) | ALDH1A1HPGDLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019013403-A1 | AGENTS FOR PREVENTING OR TREATING URINARY DISEASE AND PREPARING THE SAME | DONGKOO BIO & PHARMA CO., LTD. (KR) | 2019-01-17 | — | — | WO | claimed |
| EP-3573617-B1 | PYRAZOL-BASED COMPOUNDS FOR USE IN TREATING NASH AND CIRRHOSIS | APTABIO THERAPEUTICS INC (KR) | 2024-04-03 | — | — | EP | disclosed |
| CN-113476421-B | Controlled release composition of febuxostat and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-110248659-B | Therapeutic agent for liver disease | 阿普塔生物治疗公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-113476421-A | Controlled release composition of febuxostat and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-109985016-B | Controlled release composition of febuxostat and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2021-07-27 | — | — | CN | disclosed |
| US-10966969-B2 | Therapeutic agent for liver diseases | APTABIO THERAPEUTICS INC. (KR) | 2021-04-06 | — | — | US | disclosed |
| US-20200390752-A1 | THERAPEUTIC AGENT FOR LIVER DISEASES | APTABIO THERAPEUTICS INC. (KR) | 2020-12-17 | — | — | US | disclosed |
| CN-111405895-A | Controlled release pharmaceutical composition and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2020-07-10 | — | — | CN | disclosed |
| WO-2019013403-A1 | AGENTS FOR PREVENTING OR TREATING URINARY DISEASE AND PREPARING THE SAME | DONGKOO BIO & PHARMA CO., LTD. (KR) | 2019-01-17 | — | — | WO | disclosed |
| CN-102238946-B | Pharmaceutical composition for the controlled release of methylphenidate | SAMYANG CORP | 2014-11-26 | — | — | CN | disclosed |
| US-8465768-B2 | Pharmaceutical compositions for release control of methylphenidate | SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) | 2013-06-18 | — | — | US | disclosed |
| CN-102238946-A | Pharmaceutical composition for the controlled release of methylphenidate | SAMYANG CORP | 2011-11-09 | — | — | CN | disclosed |
| EP-2368546-A2 | PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF METHYLPHENIDATE | Samyang Corporation (KR) | 2011-09-28 | — | — | EP | disclosed |
| US-20110223247-A1 | PHARMACEUTICAL COMPOSITIONS FOR RELEASE CONTROL OF METHYLPHENIDATE | SAMYANG CORPORATION (KR) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390752-A1 | THERAPEUTIC AGENT FOR LIVER DISEASES | FABP1, LIPC, PYGL | ESR1 4626/4885ALDH1A1 414/4885ALOX15 196/4885 |
| US-10966969-B2 | Therapeutic agent for liver diseases | FABP1, LIPC, PYGL | ESR1 4626/4885ALDH1A1 414/4885ALOX15 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.